FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3045977462> ?p ?o ?g. }

• W3045977462 endingPage "671" @default.
• W3045977462 startingPage "664" @default.
• W3045977462 abstract "Linagliptin does not require dose adjustment in diabetes mellitus patients with chronic kidney disease (CKD). But, renal effects of linagliptin are not clear. Our aim was to examine the effect of linagliptin on renal disease progression in only insulin dependent type 2 diabetes mellitus (DM) patients with CKD. Stage 3–4 CKD patients were randomized into 2 groups in this prospective randomized controlled study. In the first group, linagliptin 5 mg was added in addition to the background insulin therapy. In the second group, patients continued their insulin therapy. Patients were followed up at 3-month intervals for one year. The study population consisted of 164 patients (90 patients in linagliptin group, 74 patients in other group) with a mean age of 67.5 ± 8.8 years. eGFR significantly increased in linagliptin group (p = 0.033), but decreased in other group (p = 0.003). No significant change was observed in total insulin dose in linagliptin group (p = 0.111), but in other group, total insulin dose significantly increased (p < 0.001). Proteinuria levels decreased in both groups, but there was no significant change. In the multiple logistic regression analysis, male gender and proteinuria emerged as variables that showed significant association with increased risk and the use of linagliptin emerged as variable that showed significant association with decreased risk for CKD progression. Linagliptin in DM patients with CKD was able to improve renal progression without significant effect on proteinuria and glucose control. With regard to treating diabetic nephropathy, linagliptin may offer a new therapeutic approach. La linagliptina no precisa un ajuste de la dosis en pacientes con diabetes mellitus y enfermedad renal crónica (ERC). No obstante, los efectos renales de la linagliptina no están claros. Nuestro objetivo fue examinar el efecto de la linagliptina en la evolución de la enfermedad renal únicamente en pacientes con diabetes mellitus de tipo 2 insulinodependientes con ERC. En este estudio prospectivo, aleatorizado y controlado, se asignaron de forma aleatoria pacientes con ERC en estadios 3-4 en 2 grupos. En el primer grupo se añadió linagliptina 5 mg además de la insulinoterapia de base. En el segundo grupo, los pacientes siguieron con su insulinoterapia. Los pacientes fueron objeto de seguimiento a intervalos de 3 meses durante un año. La población del estudio estuvo compuesta por 164 pacientes (90 pacientes en el grupo de linagliptina, 74 pacientes en el otro grupo) con una edad media de 67,5 ± 8,8 años. La TFGe aumentó significativamente en el grupo de linagliptina (p = 0,033), pero disminuyó en el otro grupo (p = 0,003). No se observó ningún cambio significativo en la dosis total de insulina en el grupo de la linagliptina (p = 0,111), pero, en el otro grupo, la dosis total de insulina aumentó significativamente (p < 0,001). Los niveles de proteinuria disminuyeron en ambos grupos, pero no hubo cambios significativos. En el análisis de regresión logística múltiple, el género masculino y la proteinuria destacaron como variables que mostraban una asociación significativa con el aumento del riesgo y el uso de la linagliptina destacó como variable con una asociación significativa con la disminución del riesgo de progresión de la enfermedad renal crónica. La linagliptina en pacientes con DM y ERC consiguió mejorar la evolución renal sin un efecto significativo sobre la proteinuria y el control glucémico. En lo que respecta al tratamiento de la nefropatía diabética, la linagliptina puede ofrecer un nuevo enfoque terapéutico." @default.
• W3045977462 created "2020-08-03" @default.
• W3045977462 creator A5046288234 @default.
• W3045977462 creator A5054209690 @default.
• W3045977462 creator A5074961791 @default.
• W3045977462 creator A5081479751 @default.
• W3045977462 creator A5082425927 @default.
• W3045977462 date "2020-11-01" @default.
• W3045977462 modified "2023-09-23" @default.
• W3045977462 title "The effect of linagliptin on renal progression in type-2 diabetes mellitus patients with chronic kidney disease: A prospective randomized controlled study" @default.
• W3045977462 cites W1968746497 @default.
• W3045977462 cites W1982027162 @default.
• W3045977462 cites W1988068931 @default.
• W3045977462 cites W1990841086 @default.
• W3045977462 cites W2008286952 @default.
• W3045977462 cites W2023976420 @default.
• W3045977462 cites W2033918355 @default.
• W3045977462 cites W2047680488 @default.
• W3045977462 cites W2050515508 @default.
• W3045977462 cites W2060124483 @default.
• W3045977462 cites W2065399019 @default.
• W3045977462 cites W2111538581 @default.
• W3045977462 cites W2113985146 @default.
• W3045977462 cites W2117864471 @default.
• W3045977462 cites W2120251152 @default.
• W3045977462 cites W2121162069 @default.
• W3045977462 cites W2126870113 @default.
• W3045977462 cites W2128766821 @default.
• W3045977462 cites W2138670606 @default.
• W3045977462 cites W2140980725 @default.
• W3045977462 cites W2154506215 @default.
• W3045977462 cites W2155965977 @default.
• W3045977462 cites W2158506982 @default.
• W3045977462 cites W2166051277 @default.
• W3045977462 cites W2191191124 @default.
• W3045977462 cites W2206574064 @default.
• W3045977462 cites W2310714687 @default.
• W3045977462 cites W2319556354 @default.
• W3045977462 cites W2328602797 @default.
• W3045977462 cites W2482910821 @default.
• W3045977462 cites W2528138343 @default.
• W3045977462 cites W2547768195 @default.
• W3045977462 cites W2566368688 @default.
• W3045977462 cites W2639738157 @default.
• W3045977462 cites W2775463372 @default.
• W3045977462 cites W7563278 @default.
• W3045977462 doi "https://doi.org/10.1016/j.nefro.2020.04.023" @default.
• W3045977462 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32736891" @default.
• W3045977462 hasPublicationYear "2020" @default.
• W3045977462 type Work @default.
• W3045977462 sameAs 3045977462 @default.
• W3045977462 citedByCount "2" @default.
• W3045977462 countsByYear W30459774622021 @default.
• W3045977462 crossrefType "journal-article" @default.
• W3045977462 hasAuthorship W3045977462A5046288234 @default.
• W3045977462 hasAuthorship W3045977462A5054209690 @default.
• W3045977462 hasAuthorship W3045977462A5074961791 @default.
• W3045977462 hasAuthorship W3045977462A5081479751 @default.
• W3045977462 hasAuthorship W3045977462A5082425927 @default.
• W3045977462 hasBestOaLocation W30459774621 @default.
• W3045977462 hasConcept C126322002 @default.
• W3045977462 hasConcept C126894567 @default.
• W3045977462 hasConcept C134018914 @default.
• W3045977462 hasConcept C2777180221 @default.
• W3045977462 hasConcept C2778653478 @default.
• W3045977462 hasConcept C2779306644 @default.
• W3045977462 hasConcept C2779561371 @default.
• W3045977462 hasConcept C2780031085 @default.
• W3045977462 hasConcept C2780091579 @default.
• W3045977462 hasConcept C555293320 @default.
• W3045977462 hasConcept C71924100 @default.
• W3045977462 hasConcept C90924648 @default.
• W3045977462 hasConceptScore W3045977462C126322002 @default.
• W3045977462 hasConceptScore W3045977462C126894567 @default.
• W3045977462 hasConceptScore W3045977462C134018914 @default.
• W3045977462 hasConceptScore W3045977462C2777180221 @default.
• W3045977462 hasConceptScore W3045977462C2778653478 @default.
• W3045977462 hasConceptScore W3045977462C2779306644 @default.
• W3045977462 hasConceptScore W3045977462C2779561371 @default.
• W3045977462 hasConceptScore W3045977462C2780031085 @default.
• W3045977462 hasConceptScore W3045977462C2780091579 @default.
• W3045977462 hasConceptScore W3045977462C555293320 @default.
• W3045977462 hasConceptScore W3045977462C71924100 @default.
• W3045977462 hasConceptScore W3045977462C90924648 @default.
• W3045977462 hasIssue "6" @default.
• W3045977462 hasLocation W30459774621 @default.
• W3045977462 hasLocation W30459774622 @default.
• W3045977462 hasOpenAccess W3045977462 @default.
• W3045977462 hasPrimaryLocation W30459774621 @default.
• W3045977462 hasRelatedWork W1983641721 @default.
• W3045977462 hasRelatedWork W1995945960 @default.
• W3045977462 hasRelatedWork W2026226896 @default.
• W3045977462 hasRelatedWork W2032033851 @default.
• W3045977462 hasRelatedWork W2041678535 @default.
• W3045977462 hasRelatedWork W2058152093 @default.
• W3045977462 hasRelatedWork W2066345847 @default.
• W3045977462 hasRelatedWork W2089387278 @default.
• W3045977462 hasRelatedWork W2095179743 @default.

• next